MarketCap
Facebook
X
Telegram
Gemini Therapeutics Balance Sheet 2025-2011 | GMTX
Brief overview of Gemini Therapeutics's balance sheet structure
This overview follows the five latest available annual observations between 2021 and 2025.
Assets rose from $92.4 million to $806.9 million, a gain of +773.1%, while CAGR was about 71.9%. The balance sheet expanded rapidly.
Growth in the asset base was not matched by liabilities: +773.1% versus +354.4%. The balance sheet moved in a more conservative direction.
The equity-to-assets ratio is 91.7%, compared with -69.5% five periods ago. The balance sheet has a substantial internal cushion.
The period ended with net cash: net debt stood at -$61.4 million. This supports financial flexibility.
Cash represents 11.3% of assets versus 95.3% initially, showing how the immediate liquidity reserve changed.
The balance sheet includes a negative accumulated result of -$510.2 million. It should be assessed alongside historical profits and capital distributions.
Overall assessment
Gemini Therapeutics shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet Gemini Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-61.4 M | -164 M | -358 M | -193 M | -86.4 M | -1.21 M | - | - | - | - | - | - | - | - | - |
Long Term Debt |
29.2 M | 28.3 M | 1.44 M | 1.03 M | 1.33 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
611 K | 130 K | 665 K | 307 K | 319 K | - | - | - | - | - | - | - | - | - | - |
Total Current Liabilities |
36.6 M | 23.3 M | 21.4 M | 22.6 M | 13.4 M | 598 K | - | - | - | - | - | - | - | - | - |
Total Liabilities |
67.1 M | 53.2 M | 22.9 M | 23.6 M | 14.8 M | 4.82 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-510 M | -298 M | -189 M | -112 M | -65.4 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
807 M | 497 M | 368 M | 200 M | 92.4 M | 122 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
91.1 M | 192 M | 360 M | 195 M | 88 M | 1.21 M | - | - | - | - | - | - | - | - | - |
Book Value |
740 M | 444 M | 345 M | 177 M | 77.7 M | 117 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
740 M | 444 M | 345 M | 177 M | -64.2 M | -21.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Gemini Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
59.3 M | 29.4 M | 29.2 M | 28.9 M | 28.7 M | 28.5 M | 28.3 M | 1.71 M | 1.08 M | - | 1.44 M | 1.61 M | 1.77 M | 945 K | 1.03 M | - | - | - | - | - | - | - | 14 M | 14 M | 14 M | 14 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
90.9 M | 61.8 M | 67.1 M | 57.1 M | 50.9 M | 48.9 M | 53.2 M | 27.2 M | 21.4 M | - | 22.9 M | 17.5 M | 13 M | 10.9 M | 23.6 M | 1.46 M | 6.44 M | 12.7 M | 15.6 M | 14.7 M | 14.7 M | 18.2 M | 30.2 M | 30.2 M | 30.2 M | 30.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-633 M | -574 M | -510 M | -450 M | -387 M | -332 M | -298 M | -269 M | -242 M | - | -189 M | -165 M | -151 M | -135 M | -112 M | -210 M | -207 M | -200 M | -185 M | -167 M | -148 M | -132 M | -113 M | -113 M | -113 M | -113 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
735 M | 750 M | 807 M | 630 M | 665 M | 709 M | 497 M | 495 M | 510 M | - | 368 M | 376 M | 384 M | 244 M | 200 M | 106 M | 113 M | 124 M | 140 M | 156 M | 172 M | 189 M | 8.32 M | 8.32 M | 8.32 M | 8.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
98.7 M | 88.9 M | 91.1 M | 141 M | 127 M | 123 M | 192 M | 193 M | 281 M | 343 M | 360 M | 371 M | 378 M | 236 M | 195 M | 55.6 M | 65.3 M | 74.5 M | 137 M | 150 M | 168 M | 185 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 3.31 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
644 M | 688 M | 740 M | 573 M | 614 M | 660 M | 444 M | 468 M | 489 M | - | 345 M | 359 M | 371 M | 233 M | 177 M | 105 M | 107 M | 112 M | 125 M | 141 M | 158 M | 171 M | -21.9 M | -21.9 M | -21.9 M | -21.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
644 M | 688 M | 740 M | 573 M | 614 M | 660 M | 444 M | 468 M | 489 M | 338 M | 345 M | 359 M | 371 M | 233 M | 177 M | -98.5 M | -82.8 M | -73.7 M | 125 M | 141 M | 158 M | 171 M | -21.9 M | -21.9 M | -21.9 M | -21.9 M | -10.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Gemini Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.